Curative-intent radiotherapy for pediatric osteosarcoma: The St. Jude experience.
curative intent
osteosarcoma
pediatric
radiation therapy
toxicity
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
19
10
2018
revised:
03
04
2019
accepted:
04
04
2019
pubmed:
24
4
2019
medline:
15
1
2020
entrez:
24
4
2019
Statut:
ppublish
Résumé
Radiation therapy (RT) confers local tumor control and survival advantages in some patients with osteosarcoma, yet pediatric and adolescent and young adult (AYA) population studies are limited. Twenty-eight patients treated with curative-intent RT (median dose, 59.4 Gy; range, 40-76 Gy) at our institution from 1990 to 2017 were retrospectively identified. Cumulative incidence (CIN) of local failure (LF) was estimated by Gray's method and overall survival (OS) by the Kaplan-Meier method. Competing-risk regression and Cox proportional hazards models determined predictors of outcome. Toxicity was reported according to CTCAE v4.0. With a median follow-up of 99.1 months in living patients, nine patients (32.1%) developed LF. Estimated CINs of LF with competing risk of death at 5 years for the entire cohort, patients at initial diagnosis (n = 16), and recurrent/refractory patients (n = 12) were 32.7% (95% CI, 16.0-50.5%), 25.0% (95% CI, 7.3-48.0%), and 43.8% (95% CI, 13.6-71.0%), respectively (P = 0.31). Estimated 5-year OS was 42.6% (95% CI, 23.2-62.0%), 54.6% (95% CI, 29.5-79.6%), and 24.3% (95% CI, 0-52.2%), respectively (P = 0.15). No clinicopathologic features were significantly associated with LF, yet lack of chemotherapy or metastasis at the time of RT was independent significant prognostic factors of decreased OS. Eleven patients experienced RT-related morbidity, with two grade 3 toxicities and no grade 4/5 events. Curative-intent RT in pediatric and AYA patients was well tolerated and achieved a local tumor control rate of 75% in patients with primary disease. Local control rates were similar to those in primarily adult studies, with similar or lower doses.
Sections du résumé
BACKGROUND
Radiation therapy (RT) confers local tumor control and survival advantages in some patients with osteosarcoma, yet pediatric and adolescent and young adult (AYA) population studies are limited.
METHODS
Twenty-eight patients treated with curative-intent RT (median dose, 59.4 Gy; range, 40-76 Gy) at our institution from 1990 to 2017 were retrospectively identified. Cumulative incidence (CIN) of local failure (LF) was estimated by Gray's method and overall survival (OS) by the Kaplan-Meier method. Competing-risk regression and Cox proportional hazards models determined predictors of outcome. Toxicity was reported according to CTCAE v4.0.
RESULTS
With a median follow-up of 99.1 months in living patients, nine patients (32.1%) developed LF. Estimated CINs of LF with competing risk of death at 5 years for the entire cohort, patients at initial diagnosis (n = 16), and recurrent/refractory patients (n = 12) were 32.7% (95% CI, 16.0-50.5%), 25.0% (95% CI, 7.3-48.0%), and 43.8% (95% CI, 13.6-71.0%), respectively (P = 0.31). Estimated 5-year OS was 42.6% (95% CI, 23.2-62.0%), 54.6% (95% CI, 29.5-79.6%), and 24.3% (95% CI, 0-52.2%), respectively (P = 0.15). No clinicopathologic features were significantly associated with LF, yet lack of chemotherapy or metastasis at the time of RT was independent significant prognostic factors of decreased OS. Eleven patients experienced RT-related morbidity, with two grade 3 toxicities and no grade 4/5 events.
CONCLUSIONS
Curative-intent RT in pediatric and AYA patients was well tolerated and achieved a local tumor control rate of 75% in patients with primary disease. Local control rates were similar to those in primarily adult studies, with similar or lower doses.
Identifiants
pubmed: 31012273
doi: 10.1002/pbc.27763
pmc: PMC6588458
mid: NIHMS1023576
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e27763Subventions
Organisme : NCI NIH HHS
ID : P30 CA021765
Pays : United States
Organisme : NCI NIH HHS
ID : R25 CA023944
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
J Clin Oncol. 2001 Jan 1;19(1):171-82
pubmed: 11134210
Ann Oncol. 2010 Oct;21 Suppl 7:vii320-5
pubmed: 20943636
Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):492-8
pubmed: 15667972
Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1267-71
pubmed: 10889380
Expert Rev Anticancer Ther. 2018 Jan;18(1):39-50
pubmed: 29210294
Cancer Treat Res. 2009;152:147-64
pubmed: 20213389
Cancer. 2002 Feb 15;94(4):1069-77
pubmed: 11920477
Cancer. 2011 Jun 15;117(12):2770-8
pubmed: 21656756
Bone. 2011 Sep;49(3):356-67
pubmed: 21621658
Cancer. 2012 Sep 15;118(18):4555-63
pubmed: 22359113
Radiat Res. 1994 Aug;139(2):178-84
pubmed: 8052693
Cancer. 2011 Oct 1;117(19):4522-30
pubmed: 21448934
Ann Oncol. 2016 Apr;27(4):738-44
pubmed: 26787232
Br J Cancer. 1994 Jun;69(6):1000-5
pubmed: 8198960
Radiother Oncol. 2016 Apr;119(1):30-4
pubmed: 26970678
Arch Pathol Lab Med. 1977 Jan;101(1):14-8
pubmed: 299812
J Clin Oncol. 2005 Jun 20;23(18):4031-8
pubmed: 15767644
Int J Cancer. 2017 Oct 1;141(7):1469-1477
pubmed: 28631382
Mol Clin Oncol. 2016 Jan;4(1):83-88
pubmed: 26870363
Ann Oncol. 1997 Sep;8(9):899-903
pubmed: 9358942
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
J Clin Oncol. 2003 Jan 15;21(2):334-41
pubmed: 12525527
Clin Orthop Relat Res. 1986 Mar;(204):9-24
pubmed: 3456859
Oncology. 1980;37(2):114-9
pubmed: 7360479
Pediatr Blood Cancer. 2008 May;50(5):976-82
pubmed: 18213710
Cancer Treat Res. 2009;152:3-13
pubmed: 20213383